Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) announce research group led by Professor Masahiko Kuroda, Department of Molecular Pathology, Tokyo Medical University, in collaboration with Professor Ryozo Nagai of Jichi Medical University and others, has succeeded in identifying the transcription factor KLF5 is deeply involved in the development of colorectal cancer.

 

The results were published in the American Journal of Cancer Research on May 15^th, 2014 cancer research (KLF5 Regulates the Integrity and Oncogenicity of Intestinal Stem Cells, KLF5 Regulates the Integrity and Oncogenicity of Intestinal Stem Cells | Cancer Research (aacrjournals.org)).

 

In 2001, the number of patients suffering from colorectal cancer exceeded 100,000 every year, and by 2020, it will surpass lung cancer and stomach cancer and stomach cancer is to become the number one cancer in Japan.

 

Bonac is determined to develop innovative nucleic acid drugs by utilizing the results of the endowed chair, and will continue to promote research and development so that the nucleic acid technology will serve as a bridge to drug discovery.

 

Contact:

Corporate Affairs

press@bonac.co.jp